Tag #Alzheimer

Showing 1 to 12 of 13 results

bbc.com

🌐 85% Global Worthiness

Sep 25, 07:18

Scientists Discover Brain's 'Odometer' for Distance Estimation

Researchers discovered a brain 'odometer' in mice and humans, showing that grid cells' regular firing directly correlates with accurate distance estimation, which is disrupted when environmental cues change.

Scientists Discover Brain's 'Odometer' for Distance Estimation

Researchers discovered a brain 'odometer' in mice and humans, showing that grid cells' regular firing directly correlates with accurate distance estimation, which is disrupted when environmental cues change.

Progress

4% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the significance of discovering a 'distance meter' in the brain?

This discovery reveals a fundamental mechanism for how our brains estimate distance. The research shows a direct link between the regular firing of grid cells and accurate distance perception in both mice and humans. Disruptions to this 'odometer' lead to distance estimation errors.

nrc.nl

🌐 75% Global Worthiness

Sep 20, 07:17

Dutch Television Highlights: Literature, Dementia, and Surinamese Immigration

Dutch television showcased diverse programming: a renowned author discussing his new book and the value of art; a documentary exploring music's impact on dementia patients; and a historical piece revealing discriminatory housing policies against Surinamese immigrants in 1970s Amsterdam.

Dutch Television Highlights: Literature, Dementia, and Surinamese Immigration

Dutch television showcased diverse programming: a renowned author discussing his new book and the value of art; a documentary exploring music's impact on dementia patients; and a historical piece revealing discriminatory housing policies against Surinamese immigrants in 1970s Amsterdam.

Progress

36% Bias Score

ShareSaveArticle

Quality Education

12345678

Previous 1 of 8 Next

What was the main focus of the interview with Peter Buwalda on Eva (NPO1), and what is its broader significance?

The interview focused on Buwalda's new book and the enduring value of art, especially given societal challenges. Buwalda highlighted the potential increase in art's importance amidst concerns about declining literacy rates, suggesting a growing need for meaningful cultural engagement.

lemonde.fr

🌐 75% Global Worthiness

Sep 9, 13:20

France's HAS Rejects Accelerated Approval for Alzheimer's Drug Leqembi

France's Haute Autorité de santé (HAS) rejected accelerated approval for Biogen and Eisai's Alzheimer's drug Leqembi due to modest efficacy and concerning side effects, despite its EU approval and patient advocacy.

France's HAS Rejects Accelerated Approval for Alzheimer's Drug Leqembi

France's Haute Autorité de santé (HAS) rejected accelerated approval for Biogen and Eisai's Alzheimer's drug Leqembi due to modest efficacy and concerning side effects, despite its EU approval and patient advocacy.

Progress

16% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the HAS's decision on Leqembi's availability in France?

The HAS's rejection of accelerated approval means Leqembi will not have immediate access and reimbursement in France. This decision delays broader patient access, pending a standard approval process involving further negotiations.

zeit.de

🌐 85% Global Worthiness

Aug 30, 07:15

Lecanemab (Leqembi) Alzheimer Drug Launches in Germany

Germany and Austria are the first EU countries to launch Lecanemab, a new Alzheimer's drug, on September 1st, offering treatment to a limited subset of patients due to cost and eligibility restrictions.

Lecanemab (Leqembi) Alzheimer Drug Launches in Germany

Germany and Austria are the first EU countries to launch Lecanemab, a new Alzheimer's drug, on September 1st, offering treatment to a limited subset of patients due to cost and eligibility restrictions.

Progress

16% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of Lecanemab's launch in Germany?

Lecanemab, marketed as Leqembi, is available in Germany and Austria as of September 1st. However, its impact is limited to approximately 200,000 of Germany's one million Alzheimer's patients due to eligibility criteria (only those with zero or one copy of the ApoE4 gene) and high costs (around €34,000 per year per patient).

welt.de

🌐 85% Global Worthiness

Feb 28, 19:10

EMA Recommends Approval of Alzheimer's Drug Lecanemab

The European Medicines Agency (EMA) again recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients after previously rejecting it due to safety concerns; a new analysis shows benefits outweigh risks in a specific patient subgroup; the drug is already approved in the USA.

EMA Recommends Approval of Alzheimer's Drug Lecanemab

The European Medicines Agency (EMA) again recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients after previously rejecting it due to safety concerns; a new analysis shows benefits outweigh risks in a specific patient subgroup; the drug is already approved in the USA.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the long-term implications of approving Lecanemab, particularly regarding future drug development, patient access, and healthcare resource allocation?

Lecanemab's approval, if granted by the EU Commission, signifies a potential paradigm shift in Alzheimer's treatment. The focus on early-stage intervention and subgroup analysis may influence future drug development strategies, emphasizing personalized medicine and a more nuanced approach to assessing efficacy and safety profiles. However, the drug's limited applicability raises questions about accessibility and affordability.

bbc.com

🌐 85% Global Worthiness

Jan 31, 22:08

Mice Sleep Study Reveals How Memories are Formed and Consolidated

Researchers found that mice process new and old memories during distinct sleep phases characterized by pupil size, using genetically modified mice to monitor and manipulate memory consolidation, potentially impacting AI and Alzheimer's treatment.

Mice Sleep Study Reveals How Memories are Formed and Consolidated

Researchers found that mice process new and old memories during distinct sleep phases characterized by pupil size, using genetically modified mice to monitor and manipulate memory consolidation, potentially impacting AI and Alzheimer's treatment.

Progress

32% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What methods did researchers employ to observe and manipulate memory consolidation in mice during sleep, and what were the key findings?

The study used genetically modified mice with light-sensitive neurons, allowing researchers to monitor and manipulate memory consolidation during sleep. By selectively suppressing memory-forming neurons during different pupil phases, they could erase specific memories or leave them intact. This suggests the brain actively segregates new memory formation from existing memory consolidation.

repubblica.it

🌐 85% Global Worthiness

Sep 21, 04:18

Smart Body for Alzheimer's Patients: A New Italian Project

An innovative Italian project has developed a smart body to detect and assist Alzheimer's patients experiencing disorientation, using GPS, physiological sensors, alerts, and messaging.

Smart Body for Alzheimer's Patients: A New Italian Project

An innovative Italian project has developed a smart body to detect and assist Alzheimer's patients experiencing disorientation, using GPS, physiological sensors, alerts, and messaging.

Progress

16% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the broader implications of this project for the future of Alzheimer's care?

This project demonstrates the potential of wearable technology to improve the lives of Alzheimer's patients and their caregivers. It highlights the importance of early detection and intervention, and could lead to the development of more sophisticated technologies for managing this debilitating disease.

elpais.com

🌐 85% Global Worthiness

Sep 12, 10:19

Lithium Shows Promise in Alzheimer's Prevention and Treatment

A Harvard-led study reveals that lithium, previously used to treat mood disorders, shows potential in preventing and treating Alzheimer's disease by reducing amyloid protein buildup and improving cognitive function in mice.

Lithium Shows Promise in Alzheimer's Prevention and Treatment

A Harvard-led study reveals that lithium, previously used to treat mood disorders, shows potential in preventing and treating Alzheimer's disease by reducing amyloid protein buildup and improving cognitive function in mice.

Progress

16% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does lithium impact the progression of Alzheimer's disease in the study's mouse models?

When lithium was reduced by 50% in the cerebral cortex of mice, amyloid and tau protein deposits increased significantly, leading to inflammation, synapse loss, and accelerated cognitive decline. Conversely, lithium orotate administration prevented these pathological changes.

zeit.de

🌐 85% Global Worthiness

Aug 31, 10:20

Germany and Austria First in EU to Offer Lecanemab for Early-Stage Alzheimer's

Starting September 1st, Germany and Austria will be the first EU countries to offer Lecanemab (Leqembi), a new Alzheimer's drug that slows disease progression in early stages, approved for patients with mild cognitive impairment and at most one copy of the ApoE4 gene.

Germany and Austria First in EU to Offer Lecanemab for Early-Stage Alzheimer's

Starting September 1st, Germany and Austria will be the first EU countries to offer Lecanemab (Leqembi), a new Alzheimer's drug that slows disease progression in early stages, approved for patients with mild cognitive impairment and at most one copy of the ApoE4 gene.

Progress

28% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of Lecanemab's availability in Germany and Austria?

Lecanemab, under the trade name Leqembi, will be available in Germany and Austria from September 1st, offering a new treatment option for approximately 250,000 Germans with early-stage Alzheimer's who meet specific criteria (mild cognitive impairment and at most one copy of the ApoE4 gene). The drug, costing roughly €24,000 per patient annually plus €10,000 for tests and procedures, will initially be covered by health insurance.

faz.net

🌐 75% Global Worthiness

Aug 3, 13:15

Roche Aims for Alzheimer's Cure Amidst US Trade Tensions

Roche CEO Thomas Schinecker announced plans to launch a new Alzheimer's drug within three years, while simultaneously navigating US trade challenges and committing significant investment to Germany as part of the "Made for Germany" initiative.

Roche Aims for Alzheimer's Cure Amidst US Trade Tensions

Roche CEO Thomas Schinecker announced plans to launch a new Alzheimer's drug within three years, while simultaneously navigating US trade challenges and committing significant investment to Germany as part of the "Made for Germany" initiative.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How are US trade policies impacting Roche's operations, and what strategies is the company employing to mitigate these effects?

Roche's planned Alzheimer's drug launch signifies a potential breakthrough in treating the disease. This initiative, coupled with substantial investment in Germany, demonstrates Roche's commitment to European research and development. However, the company faces ongoing challenges from US trade policies impacting pharmaceutical pricing and trade.

zeit.de

🌐 75% Global Worthiness

Feb 28, 19:10

EMA Recommends Approval of Alzheimer's Drug Lecanemab

The European Medicines Agency (EMA) recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients with mild cognitive impairment or mild dementia after a previous rejection due to safety concerns; the drug only slightly slows disease progression and is suitable for a small patient su...

EMA Recommends Approval of Alzheimer's Drug Lecanemab

The European Medicines Agency (EMA) recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients with mild cognitive impairment or mild dementia after a previous rejection due to safety concerns; the drug only slightly slows disease progression and is suitable for a small patient su...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the significance of the EMA's recommendation to approve Lecanemab for Alzheimer's disease?

The European Medicines Agency (EMA) recommends approving Lecanemab, an Alzheimer's drug targeting underlying disease processes, for early-stage Alzheimer's patients with mild cognitive impairment or mild dementia. This follows a previous rejection due to safety concerns, but a new review found the benefits outweigh risks in a specific patient subgroup with a lower likelihood of severe side effects like brain swelling and microbleeds. The drug only slightly delays disease progression and is suitable for a small percentage of patients.

welt.de

🌐 85% Global Worthiness

Jan 25, 19:09

Study Links Certain Medications to Reduced Dementia Risk

A Cambridge University study analyzing data from over 130 million health records found that use of antibiotics, antivirals, and anti-inflammatory drugs correlated with a lower dementia risk, supporting the "infection hypothesis" of Alzheimer's disease and suggesting potential for repurposing existin...

Study Links Certain Medications to Reduced Dementia Risk

A Cambridge University study analyzing data from over 130 million health records found that use of antibiotics, antivirals, and anti-inflammatory drugs correlated with a lower dementia risk, supporting the "infection hypothesis" of Alzheimer's disease and suggesting potential for repurposing existin...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the potential implications of this research for pharmaceutical companies and future dementia treatment strategies?

The findings highlight the potential for repurposing existing drugs to combat dementia, a significant public health challenge. The study suggests that focusing on the right drug at the right stage of the disease, potentially before cognitive decline begins, could be crucial. Further research is needed to determine causal relationships and address data limitations, but the results offer a new avenue for drug development.

Showing 1 to 12 of 13 results